MTOR and epilepsy: As discussed above, the epileptogenic action of the d-2-HG oncometabolite and its ability to activate the mTOR pathway open up the potential use of mTOR inhibitors as rapamycin, everolimus, and temserolimus for patients with IDH1 mutated tumors and drug refractory epilepsy [38].